Health Care [ 4/12 ] | Biotechnology [ 14/75 ]
NASDAQ | Common Stock
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite.
The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B.
In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers.
The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 18, 26 | 0.06 Decreased by -14.29% | 0.10 Decreased by -40.00% |
| Nov 10, 25 | 0.29 Increased by +314.29% | 0.09 Increased by +222.22% |
| Aug 13, 25 | 0.19 Increased by +137.50% | 0.08 Increased by +137.50% |
| May 6, 25 | 0.07 Increased by +75.00% | 0.07 Increased by +3.70% |
| Mar 4, 25 | 0.07 Decreased by -22.22% | 0.05 Increased by +31.33% |
| Nov 11, 24 | 0.07 Increased by +16.67% | 0.07 |
| Aug 14, 24 | 0.08 Increased by +100.00% | 0.06 Increased by +33.33% |
| May 8, 24 | 0.04 Increased by +200.00% | 0.06 Decreased by -33.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 45.60 M Increased by +16.91% | 3.64 M Decreased by -4.53% | Increased by +7.97% Decreased by -18.34% |
| Sep 30, 25 | 47.01 M Increased by +12.63% | 5.30 M Increased by +37.10% | Increased by +11.27% Increased by +21.73% |
| Jun 30, 25 | 44.75 M Increased by +5.37% | 7.38 M Increased by +66.65% | Increased by +16.48% Increased by +58.15% |
| Mar 31, 25 | 44.02 M Increased by +16.65% | 3.96 M Increased by +67.61% | Increased by +9.01% Increased by +43.69% |
| Dec 31, 24 | 39.01 M Increased by +7.06% | 3.81 M Decreased by -24.71% | Increased by +9.76% Decreased by -29.68% |
| Sep 30, 24 | 41.74 M Increased by +10.03% | 3.86 M Increased by +19.86% | Increased by +9.25% Increased by +8.93% |
| Jun 30, 24 | 42.47 M Increased by +13.43% | 4.43 M Increased by +144.26% | Increased by +10.42% Increased by +115.34% |
| Mar 31, 24 | 37.74 M Increased by +22.88% | 2.37 M Increased by +230.74% | Increased by +6.27% Increased by +206.39% |